Introduction and objective:
Bipolar Disorder (BD) is a chronic mental condition associated with significant impairment of psychosocial functioning and premature mortality due to somatic comorbidities, as well as high rates of completed suicides. Unfortunately, results of currently available methods of treatment are unsatisfactory. Thus, new therapeutic solutions are sought. Recently, particular attention has been paid to the use of nutraceuticals, especially Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs), as an adjunctive treatment in various mental disorders. The aim of the review is to show the role of PUFAs in the pathogenesis of BD, and present results of already conducted studies investigating n-3 PUFAs supplementation effects on the BD clinical course.

Materials and Method:
Internet scientific bases were searched throughout January and February 2024 for the relevant to this topic literature from the past 15 years, using keywords: “bipolar disorder”, “cardiovascular risk”, “mental disorders”, “omega-3 fatty acids”, “polyunsaturated fatty acids”, “remission”, “treatment”. Original and review articles were included. Manuscripts in other language than English were excluded from the search. To assess the proper quality of this manuscript, the Scale for the Assessment of Narrative Review Articles were used.

Brief description of the state of knowledge:
There is lack of research assessing the importance of n-3 PUFAs in the treatment of BD. However, it seems that their supplementation may bring significant benefits in the acute phase of depression episode treatment, remission maintenance and reduction in cardiometabolic risk factors.

Results of already conducted studies should be treated as a rationale for future research. It is highly recommended to confirm the n-3 PUFAs efficiency in the BD treatment, to justify their widespread use in everyday clinical practice.

Nierenberg AA, Agustini B, Köhler-Forsberg O, et al. Diagnosis and Treatment of Bipolar Disorder: A Review. JAMA. 2023;330(14):1370–1380.
Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol. 2018;8(9):251–269.
Biazus TB, Beraldi GH, Tokeshi L, et al. All-cause and cause-specific mortality among people with bipolar disorder: a large-scale systematic review and meta-analysis. Mol Psychiatry. 2023;28(6):2508–2524.
Chow RTS, Whiting D, Favril L, et al. An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs. Neurosci Biobehav Rev. 2023;155:105454.
Kishi T, Matsuda Y, Sakuma K, et al. Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis. Psychol Med. 2021;51(15):2721–2729.
Hett D, Morales-Muñoz I, Durdurak BB, et al. Rates and associations of relapse over 5 years of 2649 people with bipolar disorder: a retrospective UK cohort study. Int J Bipolar Disord. 2023;11(1):23.
Prakash SE, Manjunatha VC, Nagella P, et al. Nutraceuticals to prevent and manage cardiovascular diseases. Nutraceuticals. 2023;269–291.
Lange KW. Omega-3 Fatty Acids and Mental Health. Glob. Health J. 2020;4:18–30.
Koga N, Ogura J, Yoshida F, et al. Altered polyunsaturated fatty acid levels in relation to proinflammatory cytokines, fatty acid desaturase genotype, and diet in bipolar disorder. Transl Psychiatry. 2019;9(1):208.
Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:1–7.
Redruello-Requejo M, Samaniego-Vaesken ML, Puga AM, et al. Omega-3 and Omega-6 Polyunsaturated Fatty Acid Intakes, Determinants and Dietary Sources in the Spanish Population: Findings from the ANIBES Study. Nutrients. 2023;15(3):562.
Messamore E, McNamara RK. Detection and treatment of omega-3 fatty acid deficiency in psychiatric practice: Rationale and implementation. Lipids Health Dis. 2016;15:25.
Balanzá-Martínez V, Fries GR, Colpo GD, et al. Therapeutic use of omega-3 fatty acids in bipolar disorder. Expert Rev Neurother. 2011;11(7):1029–1047.
Zárate R, El Jaber-Vazdekis N, Tejera N, et al. Significance of long chain polyunsaturated fatty acids in human health. Clin Transl Med. 2017;6(1):25.
Nguyen QV, Malau-Aduli BS, Cavalieri J, et al. Enhancing Omega-3 Long-Chain Polyunsaturated Fatty Acid Content of Dairy-Derived Foods for Human Consumption. Nutrients. 2019;11(4):743.
Chaves H, Singh RB, Khan S, et al. High Omega-6/Omega-3 Fatty Acid Ratio Diets and Risk of Noncommunicable Diseases: Is the Tissue, the Main Issue? Role Funct Food Secur Glob Heal. 2019;217–259.
Innes JK, Calder PC. Omega-6 fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids. 2018;132:41–48.
Williams NC, Hunter KA, Shaw DE, et al. Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6·2 and 3·1 g/d of long-chain n-3 PUFA in adults with asthma. Br J Nutr. 2017;117(10):1379–1389.
Limbu R, Cottrell GS, McNeish AJ. Characterisation of the vasodilation effects of DHA and EPA, n-3 PUFAs (fish oils), in rat aorta and mesenteric resistance arteries. PLoS One. 2018; 13(2): e0192484.
Adili R, Hawley M, Holinstat M. Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids. Prostaglandins Other Lipid Mediat. 2018;139:10–18.
Oppedisano F, Macrì R, Gliozzi M, et al. The Anti-Inflammatory and Antioxidant Properties of n-3 PUFAs: Their Role in Cardiovascular Protection. Biomedicines. 2020;8(9):306.
Evans SJ, Ringrose RN, Harrington GJ, et al. Dietary intake and plasma metabolomic analysis of polyunsaturated fatty acids in bipolar subjects reveal dysregulation of linoleic acid metabolism. J Psychiatr Res. 2014;57:58–64.
Rapoport SI. Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chem Neurosci. 2014;5(6):459–467.
Wen J, Satyanarayanan SK, Li A, et al. Unraveling the impact of Omega-3 polyunsaturated fatty acids on blood-brain barrier (BBB) integrity and glymphatic function. Brain Behav Immun. 2024;115:335–355.
Bozzatello P, Rocca P, Mantelli E, et al. Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders? Int J Mol Sci. 2019;20(21):5257.
Benedetti F, Aggio V, Pratesi ML, et al. Neuroinflammation in Bipolar Depression. Front Psychiatry. 2020;11:71.
Lo Van A, Hachem M, Lagarde M, et al. Omega-3 Docosahexaenoic Acid Is a Mediator of Fate-Decision of Adult Neural Stem Cells. Int J Mol Sci. 2019;20(17):4240.
Zhou L, Xiong JY, Chai YQ, et al. Possible antidepressant mechanisms of omega-3 polyunsaturated fatty acids acting on the central nervous system. Front Psychiatry. 2022;13:933704.
Di Miceli M, Bosch-Bouju C, Layé S. PUFA and their derivatives in neurotransmission and synapses: a new hallmark of synaptopathies. Proc Nutr Soc. 2020;79(4):388–403.
Lee JG, Woo YS, Park SW, et al. Neuromolecular Etiology of Bipolar Disorder: Possible Therapeutic Targets of Mood Stabilizers. Clin Psychopharmacol Neurosci. 2022;20(2):228–239.
Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73(1):81–86.
Murphy BL, Stoll AL, Harris PQ, et al. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol. 2012;32(5):699–703.
Shakeri J, Khanegi M, Golshani S, et al. Effects of Omega-3 Supplement in the Treatment of Patients with Bipolar I Disorder. Int J Prev Med. 2016;7:77.
Eslahi H, Shakiba M, Saravani M, et al. The effects of omega 3 fatty acids on the serum concentrations of pro inflammatory cytokines anddepression status in patients with bipolar disorder: A randomized double-blind controlled clinical trial. J Res Med Sci. 2023;28:36.
Saunders EFH, Mukherjee D, Myers T, et al. Adjunctive dietary intervention for bipolar disorder: a randomized, controlled, parallel-group, modified double-blinded trial of a high n-3 plus low n-6 diet. Bipolar Disord. 2022;24(2):171–184.
Sarris J, Ravindran A, Yatham LN, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry. 2022;23(6):424–455.
Belete H, Ali T, Legas G. Relapse and Clinical Characteristics of Patients with Bipolar Disorders in Central Ethiopia: A Cross-Sectional Study. Psychiatry J. 2020;2020:8986014.
Zailani H, Wu SK, Yang KJ, et al. Omega-3 polyunsaturated fatty acids in the prevention of relapse in patients with stable bipolar disorder: A 6-month pilot randomized controlled trial. Psychiatry Res. 2024;331:115633.
McPhilemy G, Byrne F, Waldron M, et al. A 52-week prophylactic randomised control trial of omega-3 polyunsaturated fatty acids in bipolar disorder. Bipolar Disord. 2021;23(7):697–706.
Biazus TB, Beraldi GH, Tokeshi L, et al. All-cause and cause-specific mortality among people with bipolar disorder: a large-scale systematic review and meta-analysis. Mol Psychiatry. 2023;28(6):2508–252.
Paljärvi T, Herttua K, Taipale H, et al. Cause-specific excess mortality after first diagnosis of bipolar disorder: population-based cohort study. BMJ Ment Health. 2023;26(1):e300700.
Preuss UW, Schaefer M, Born C, et al. Bipolar Disorder and Comorbid Use of Illicit Substances. Medicina (Kaunas). 2021;57(11):1256.
Tew GA, Bailey L, Beeken RJ, et al. Physical Activity in Adults with Schizophrenia and Bipolar Disorder: A Large Cross-Sectional Survey Exploring Patterns, Preferences, Barriers, and Motivating Factors. Int J Environ Res Public Health. 2023;20(3):2548.
Dou W, Yu X, Fang H, et al. Family and Psychosocial Functioning in Bipolar Disorder: The Mediating Effects of Social Support, Resilience and Suicidal Ideation. Front Psychol. 2022;12:807546.
Rogalski JK, Subdys A, Gawlik-Kotelnicka OE. The development of the Metabolic-associated Fatty Liver Disease during pharmacotherapy of mental disorders – a review. Curr Probl Psychiatry. 2022;23(3):128–143.
Wulsin LR, Blom TJ, Durling M, et al. Cardiometabolic risks and omega-3 index in recent-onset bipolar I disorder. Bipolar Disord. 2018;20(7):658–665.
Bruno GM, Dovera F, Ciccarone A, et al. Overview of Nutraceuticals and Cardiometabolic Diseases following Socio-Economic Analysis. Endocrines. 2022;3(2):255–295.
O'Mahoney LL, Matu J, Price OJ, et al. Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. Cardiovasc Diabetol. 2018;17(1):98.
Li JJ, Dou KF, Zhou ZG, et al. Role of omega-3 fatty acids in the prevention and treatment of cardiovascular Diseases: A consensus statement from the Experts› Committee Of National Society Of Cardiometabolic Medicine. Front Pharmacol. 2022;13:1069992.
Sherratt SCR, Libby P, Budoff MJ, et al. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Curr Atheroscler Rep. 2023;25(1):1–17.
Journals System - logo
Scroll to top